Atlas Trials

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

Clinical trial NCT00793377 · COMPLETED

Trial details

NCT number
NCT00793377
Sponsor
GBG Forschungs GmbH
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Primary Breast Cancer
Enrollment
913

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.